Author:
Ammar Shahed,Borghoff Kathleen,El Mikati Ibrahim K.,Mustafa Reem A.,Noureddine Lama
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS (2017) Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant 32(8):1356–1363
2. Kalot MA, El Alayli A, Al Khatib M, Husainat N, McGreal K, Jalal DI et al (2021) A computable phenotype for autosomal dominant polycystic kidney disease. Kidney 360 2(11):1728–1733
3. Shivade C, Raghavan P, Fosler-Lussier E, Embi PJ, Elhadad N, Johnson SB et al (2014) A review of approaches to identifying patient phenotype cohorts using electronic health records. J Am Med Inform Assoc 21(2):221–230
4. Soroka S, Alam A, Bevilacqua M, Girard LP, Komenda P, Loertscher R et al (2018) Updated Canadian expert consensus on assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease. Can J Kidney Health Dis 5:2054358118801589
5. Ahmad FS, Ricket IM, Hammill BG, Eskenazi L, Robertson HR, Curtis LH et al (2020) Computable phenotype implementation for a National, Multicenter Pragmatic Clinical Trial. Circ: Cardiovasc Qual Outcomes 13(6):e006292